Two medicines, side by side
Mirabegron vs solifenacin
Mirabegron and solifenacin are both labeled for overactive bladder. Drugs@FDA records approvals of mirabegron since 2012 and of solifenacin since 2004. Pharmacies paid $9.39 per mirabegron ER 50 mg tablet and $0.162 per solifenacin 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, mirabegron is a beta3-adrenergic agonist and solifenacin a cholinergic muscarinic antagonist.
Check it at the source: the mirabegron FDA label on DailyMed (effective December 24, 2025); the solifenacin FDA label on DailyMed (effective February 4, 2026).
Highlights of the mirabegron record
Mirabegron (Myrbetriq) · label of December 24, 2025
Used for
From the label: indicationsMirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. […]
On the market
- Earliest approval on file
- June 28, 2012
- Generic labelers
- 8 labelers
- Pharmacy cost
- $9.39 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the solifenacin record
Solifenacin (Vesicare) · label of February 4, 2026
Used for
From the label: indicationsSolifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
On the market
- Earliest approval on file
- November 19, 2004
- Generic labelers
- 20 labelers
- Pharmacy cost
- $0.162 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 6
Source: FDA drug labels via openFDA (Mirabegron label of December 24, 2025, Solifenacin label of February 4, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do mirabegron and solifenacin differ on the record?
In FDA's classes, mirabegron is a beta3-adrenergic agonist and solifenacin a cholinergic muscarinic antagonist.
How each works, in its label's words: Mirabegron, “Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR.”; Solifenacin, “Solifenacin is a competitive muscarinic receptor antagonist.”
Half-life, in each label's words: Mirabegron, “Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) …”; Solifenacin, “Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.”
Generics: mirabegron since 2019; solifenacin since 2014 (Drugs@FDA).
| Mirabegron | Solifenacin | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Pharmacologic class | beta3-Adrenergic Agonist | Cholinergic Muscarinic Antagonist |
| How it works (label) | Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. | Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle. |
| Half-life (label) | Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) of mirabegron is approximately 50 hours in patients. | Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours. |
| Earliest approval on file (Drugs@FDA) | June 28, 2012 | November 19, 2004 |
| First generic approved | December 27, 2019 | April 2, 2014 |
| Generic labelers (NDC) | 8 labelers | 20 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $9.39 per tablet (Mirabegron ER 50 mg tablet) | $0.162 per tablet (Solifenacin 10 mg tablet) |
| 12-month price change | -2% | -3% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 6 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 38,466 | 1,846 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Mirabegron label, drug interactionsWhen initiating a combination of mirabegron and digoxin with or without solifenacin succinate, use the lowest dose of digoxin; monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect.
Mirabegron label, warnings and precautionsIn contrast, in adult OAB patients in clinical trials, MYRBETRIQ, taken as monotherapy or in combination with solifenacin succinate 5 mg, the mean increase in systolic and diastolic blood pressure at the maximum recommended mirabegron dose of 50 mg was approximately 0.5 to 1 mm Hg greater than placebo.
Source: FDA drug labels via openFDA
What next?
- Alternatives to mirabegron
- every medicine labeled for the same conditions